| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 15, 2024 5:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
Net income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue up 54% sequentially$20.1 million cash balance at September 30, 2024Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flowRyan Selhorn promoted to Chief Financial OfficerCompany to host conference call and webcast today, November 13, 2024, at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / November 13, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today ann
DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the market close on Wednesday, November 13, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, November 13, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Wednesday, November 13, 2024, at 4:30 p.m. Eastern timeCall-in Information: Interested parties can access the conference call by dialing (877) 545-
Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 millionFull year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023$20.0 million cash balance at June 30, 2024Company expects Rx Segment net revenue and adjusted EBITDA growth in fiscal 2025 from current levelsCompany to host conference call and webcast today, September 26, 2026, at 4:30 p.m. Eastern timeDENVER, CO / ACCESSWIRE / September 26, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel ther
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
3 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
Webcasted presentation to take place at 1:10pm ETDENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023.Mr. Disbrow will conduct a presentation and subsequently open the floor to questions. Please submit your questions in advance to [email protected]'s presentation will be on Thursday, December 7th at 1:10pm ET. To register to stream the presentation live, visit this LINK or visit the Company's website.If attendees are not able to
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Mark Oki will join Aytu as the company's chief financial officer effective January 17, 2022. Mr. Oki will serve as a member of Aytu's executive committee and will report to Josh Disbrow, chief executive officer. Mr. Oki will provide leadership and oversight of the company's financial operations and planning, accounting, information technology and select other functions."On behalf of the entire company, I am delighted to welcome Mark to Aytu and look forward to partnering with him as we
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company -- Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline -- Record quarter for consumer health division with revenue reaching $8.4 million and Rx division revenue up 9% over same quarter last year -- Grew leadership team with three executives including CFO, Rich Eisenstadt - - Management to host live conference call and webcast today at 4:30 p.m. ET -ENGLEWOOD, CO / ACCESSWIRE / May 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commerciali
Cantor Fitzgerald initiated coverage of Aytu BioPharma with a rating of Overweight and set a new price target of $11.00
SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13D/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
10-Q - AYTU BIOPHARMA, INC (0001385818) (Filer)
8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that CEO, Josh Disbrow, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.The fireside chat will take place at 10:00 a.m. Eastern Time on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/health2025/ or directly at https://lythampartners.com/health2025/aytu. A replay of the fireside chat will also be available through same links.1
DENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LITIGATION STYLED WITMER V. ARMISTICE CAPITAL LLC, ET AL., NO. 2022-0807-MTZ (THE "ACTION").TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF AYTU BIOPHARMA, INC. ("AYTU" OR THE "COMPANY") (NASDAQ:AYTU) AS OF OCTOBER 9, 2024 (THE "RECORD DATE") ("CURRENT AYTU SHAREHOLDERS").YOU ARE HEREBY NOTIFIED that the Settling Parties to the Action have reached a settlement ("Settlement") to resolve the issues raised in the Action against Defendants
DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year."We are honored to be recognized for the fourth consecutive year as a member of the Deloitte Technology Fast 500 list of the most rapidly growing companies," commented Josh Disbrow, Chief Executive Officer of Aytu BioPharma. "During fiscal 2024, we continued to successfully reposition